9 research outputs found

    Abstract Number ‐ 157: Effect of Antiplatelet Therapy in Acute Ischemic Stroke with Tandem Lesions

    No full text
    Introduction Recent studies have shown beneficial effects of Carotid artery stenting (CAS) in acute ischemic stroke patients with tandem lesions (TL). However, stent placement requires the use of antiplatelet medications to prevent in‐stent thrombosis and re‐occlusion of the artery. This must be balanced with the risk of intracerebral hemorrhage. In this multicenter study, we aimed to investigate the safety and feasibility of using antiplatelet regimens in patients with anterior circulation stroke with TLs. Methods Patient level data were pooled from 17 centers and included patients with intracranial occlusion of ICA or M1/M2 segment of MCA with a concomitant extracranial ICA occlusion or stenosis ≥ 50%. Inclusion criteria were; age ≥ 18 years, EVT for intracranial occlusion, and underwent treatment for extracranial ICA lesions demonstrated on CTA and/or DSA. Patients were divided into groups according to the number of antiplatelets administered at the time of endovascular therapy (EVT) procedure into four groups including; 1) no antiplatelets, 2) single oral antiplatelet, 3) dual antiplatelets, and 4) intravenous antiplatelets (in combination of single or dual antiplatelets). Multivariable logistic regression models with multiple imputations were built to assess the association of primary outcome; symptomatic intracranial hemorrhage (sICH), and secondary outcomes including; modified Rankin Score (mRS) 0–2 at 90 days, and successful reperfusion (mTICI score ≥ 2b). Results A total of 682 patients were included. Of these, 138 (20.2%) did not receive any antiplatelet therapy, while 143 (20.97%) were treated with single oral, 207 (30.35%) with dual oral, and 194 (28.5%) with intravenous combined with single or dual antiplatelets. The rate of favorable outcome was non‐significantly higher in the dual (53%) and IV‐combination (54.4%) antiplatelets, as compared with single (38.9%) and without antiplatelet (38.6%) medications. In the multivariable model, after adjusting, there was no significant differences in the sICH (single: aOR: 1.07, CI: 0.62‐1.84, p = 0.8, dual: aOR: 1.18, CI: 0.70‐1.99, p = 0.55, IV‐combination: aOR: 1.01, CI: 0.57‐1.78, p = 0.98) and functional outcome at 90 days (single: aOR: 1.15, CI: 0.63‐2.12, p = 0.64, dual: aOR: 1.03, CI: 0.55‐1.9, p = 0.9, IV‐combination: aOR: 0.83, CI: 0.42‐1.64, p = 0.59) among the study groups. Interestingly, successful reperfusion (mTICI score ≥ 2b) was significantly higher in dual oral and IV‐combination antiplatelets (single: aOR: 1.14, CI: 0.61‐2.14, p = 0.69, dual: aOR: 4.82, CI: 2.23‐10.42, p = < 0.001, IV‐combination: aOR: 3.65, CI: 1.71‐7.79, p = 0.001). Conclusions Administration of antiplatelet medications during EVT was associated with successful reperfusion without increasing the rate of symptomatic hemorrhage in patients with anterior circulation LVO with TLs. Further large‐scale randomized studies are warranted to validate the optimal antiplatelet regimens during acute carotid artery stenting in patients with TLs

    Abstract Number ‐ 181: Anterograde versus Retrograde approaches in the Endovascular Management of Tandem Lesions

    No full text
    Introduction There are two approaches for treating stroke patients with tandem occlusions: the anterograde approach (AA, extracranial lesions first) and the retrograde approach (RA, intracranial lesion first). Both techniques are associated with favorable functional outcomes. We aimed to compare both techniques for efficacy and safety outcomes in a multicenter study. Methods Patient data were pooled from 17 centers and divided into AA and RA groups. We performed multivariable logistic regressions to evaluate the association between each group with efficacy and safety outcomes. Results 552 patients were included in the study, 270 (48.4%) were treated with the AA, and 288 (51.6%) with the RA. There were no differences between groups for functional outcome (mRS 0–2) at 90 days (aOR = 0.93, 95%CI: 0.58‐1.48, p = 0.75), and successful reperfusion [mTICI >2b] (aOR = 0.83, 95%CI: 0.44‐1.56, p = 0.57). Similarly, we did not observe any differences for safety outcomes related to sICH (OR = 0.57, 95%CI: 0.25‐1.29, p = 0.18), parenchymal hematoma type 2 (OR = 0.61, 95%CI: 0.3‐1.22, p = 0.16), and all‐cause mortality at 90 days (OR = 1.22, 95%CI: 0.66‐2.26, p = 0.52). However, the median puncture‐to‐reperfusion time was higher in AA compared with RA [59 minutes (IQR: 38–92) vs 53.5 minuntes (IQR: 37–87)]. Conclusions The AA and RA approaches for the treatment of tandem occlusions seem to achieve similar efficacy and safety outcomes. These results are consistent with those of a previous multi‐center study. Additionally, and in line with previous research, there is a puncture‐to‐reperfusion time difference between both approaches, which suggests a potential benefit when using the RA. However, further prospective randomized studies are needed to elucidate its benefit in achieving better clinical outcomes

    Abstract Number: LBA2 Early versus Late Window in the Endovascular Management of Acute Tandem Lesions

    No full text
    Introduction Despite the irrefutable benefit of mechanical thrombectomy for patients with isolated intracranial large vessel occlusions (LVO), the effect of endovascular treatment in patients with tandem lesions remains unclear. In this study from the multi‐center PICASSO registry, we compare efficacy and safety outcomes in TLs patients treated in the early versus late window. Methods In this study, we used the data from the multi‐center PICASSO (Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem Occlusion Thrombectomy) registry. PICASSO collaboration is a retrospective observational registry from 17 stroke centers. We compared efficacy and safety outcomes in TLs patients treated in the early versus late window. Patients were divided into two groups depending on last known well (LKW) to puncture time: Early time‐window group (<6 hours), and late time‐window group (6‐24 hours).We performed multivariable logistic and multinomial regressions to evaluate the association between each group and efficacy and safety outcomes, Results 628 patients were included in the study. There were 336 (53.5%) treated in the early time‐window and 292 (46.5%) in the late time‐window. We did not observe a statistically significant difference between groups mRS 0–2 at 90 days (46.5% vs. 49%, aOR = 1.51, 95%CI: 0.92‐2.57, p = 0.101), shift analysis of mRS (aOR = 0.93, 95%CI: 0.63‐1.38, p = 0.734), and increased time from LKW to puncture was not significantly associated with mRS 0–2 at 90 days (aOR = 1.05, 95% CI: 0.99‐1.11, p = 0.09 for each hour delay). Similarly, we did not find differences in hemorrhagic transformation of ischemic stroke types: symptomatic ICH (5.1% vs. 4.1%, aOR = 0.80, 95%CI: 0.34‐1.88, p = 0.604), parenchymal hematoma type 2 (8.1% vs. 6.9%. aOR = 0.85, 95%CI: 0.44‐1.66, p = 0.641), and in ordinal analysis of petechial hemorrhage (19.8% vs 24.7%, aOR = 1.15, 95%CI: 0.79‐1.66), p = 0.466). Additionally, there were no differences in rates of successful reperfusion (mTICI 2b‐3) (88.7% vs. 85.2%, aOR = 1.19, 95%CI: 0.67‐2.11, p = 0.546), first pass effect (61.1% vs. 56.9%, aOR = 1.01, 95%CI: 0.65‐1.56, p = 0.963), early neurological improvement (44.1% vs. 36.7%, aOR = 0.96, 95%CI: 0.64‐1.44, p = 0.833), mortality at 90‐days (15.2% vs. 19.2%, aOR = 1.62, 95%CI: 0.94‐2.8, p = 0.81) and in‐hospital mortality (9.8% vs. 10.5%, aOR = 1.28, 95% CI 0.68‐2.39, p = 0.441). Conclusions The therapeutic effect of endovascular therapy in patients with AIS due to tandem lesions who present in the late time‐window is similar to those presenting in the early time‐window. Furthermore, efficacy and safety outcomes rates are consistent with those found in clinical trials that included patients with isolated intracranial lesions treated in the late time‐window
    corecore